A PHASE 2A, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF MULTIPLE SUBCUTANEOUS DOSES OF TRIV-509 IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

Registry ID

509-101

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

TRIVENI BIO, INC.

Start date

2025-10-14

Last update

2025-09-18

Conditions

• ATOPIC DERMATITIS

Related clinical trials

• A PHASE 2B, MULTICENTER, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CAMOTESKIMAB IN ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
• A PHASE 2B, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF JNJ-95597528 FOR THE TREATMENT OF ADULT PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
• A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF GALVOKIMIG IN ADULT STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
• A MULTICENTER, RANDOMIZED, PARTICIPANT- AND INVESTIGATOR -BLINDED, PLACEBO-CONTROLLED, PHASE 2A STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF GIA632 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
• A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, DOSE-RANGING STUDY WITH AN OPEN-LABEL PERIOD INVESTIGATING THE EFFICACY AND SAFETY PROFILE OF KT-621 ADMINISTERED ORALLY TO PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS.
• AN EXTENSION STUDY TO EVALUATE THE LONG- TERM SAFETY AND EFFICACY OF AFIMKIBART (RO7790121) IN PATIENTS WITH ATOPIC DERMATITIS WHO PARTICIPATED IN PREVIOUS AFIMKIBART CLINICAL TRIALS

View on source registry